Rep. Maria Elvira Salazar Buys Moderna, Inc. (NASDAQ:MRNA) Shares

Representative Maria Elvira Salazar (Republican-Florida) recently bought shares of Moderna, Inc. (NASDAQ:MRNA). In a filing disclosed on September 09th, the Representative disclosed that they had bought between $1,001 and $15,000 in Moderna stock on August 19th. The trade occurred in the Representative’s “UBS IRA ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of International Business Machines (NYSE:IBM) on 8/24/2026.
• Sold $1,001 – $15,000 in shares of Moderna (NASDAQ:MRNA) on 8/19/2026.
• Sold $1,001 – $15,000 in shares of Qualcomm (NASDAQ:QCOM) on 8/19/2026.
• Purchased $15,001 – $50,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 8/19/2026.
• Sold $15,001 – $50,000 in shares of Chubb (NYSE:CB) on 8/19/2026.
• Sold $1,001 – $15,000 in shares of Qualcomm (NASDAQ:QCOM) on 8/12/2026.
• Purchased $1,001 – $15,000 in shares of SpaceX (NASDAQ:SPCX) on 8/12/2026.
• Purchased $1,001 – $15,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 8/7/2026.
• Purchased $1,001 – $15,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 7/28/2026.
• Purchased $15,001 – $50,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 7/28/2026.

Moderna Stock Performance

MRNA opened at $143.97 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. The business’s 50-day simple moving average is $92.35 and its 200 day simple moving average is $66.74. The firm has a market capitalization of $57.48 billion, a PE ratio of -18.02 and a beta of 1.10. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $176.66.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $0.06. The company had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. Moderna’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($2.13) EPS. As a group, sell-side analysts expect that Moderna, Inc. will post -6.09 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, President Stephen Hoge sold 53,336 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the transaction, the president directly owned 1,483,848 shares of the company’s stock, valued at $76,225,271.76. The trade was a 3.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the transaction, the insider directly owned 74,129 shares in the company, valued at approximately $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 10.80% of the stock is currently owned by insiders.

Key Stories Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Momentum and upcoming data readouts supported the stock. Moderna rallied in Friday morning trading despite limited movement among peers. UBS reportedly identified three near-term “INT” data readouts, potentially giving investors multiple upcoming catalysts to anticipate. However, the reports did not provide detailed results or confirm that any readout will be positive. Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat Moderna Set for 3 Near-Term INT Data Readouts, UBS Says
• Neutral Sentiment: Congressional trading coverage offers no clear Moderna-specific catalyst. A report discussing recent stock transactions by members of Congress included Moderna-related investor-monitoring activity, but it did not identify a material change in the company’s outlook or operations. Congressional Stock Transactions
• Neutral Sentiment: Short-interest data appears unreliable. The report listed both current and prior short interest at zero and calculated a zero-day short-interest ratio, with an invalid percentage change. Therefore, it provides little useful information about short-covering or bearish positioning in Moderna.
• Negative Sentiment: Industry commercialization hurdles remain a risk. Manufacturing complexity and other barriers could slow the development and commercialization of personalized mRNA cancer vaccines, highlighting longer-term execution risks for Moderna and its peers. mRNA Cancer Vaccines’ Biggest Barriers to Market

Wall Street Analyst Weigh In

Several brokerages recently commented on MRNA. Piper Sandler reaffirmed an “overweight” rating on shares of Moderna in a report on Monday, August 3rd. Argus upgraded Moderna from a “hold” rating to a “buy” rating and set a $180.00 price objective for the company in a report on Friday, August 28th. CLSA upgraded Moderna to an “outperform” rating in a research note on Friday, August 28th. Deutsche Bank Aktiengesellschaft assumed coverage on Moderna in a report on Friday, August 28th. They issued a “hold” rating on the stock. Finally, Jefferies Financial Group reissued a “hold” rating on shares of Moderna in a report on Wednesday, August 19th. Seven analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat.com, Moderna has a consensus rating of “Hold” and a consensus price target of $76.72.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. MUFG Securities EMEA plc acquired a new position in Moderna in the 2nd quarter worth about $28,000. Allied Private Wealth LLC bought a new stake in Moderna during the 2nd quarter worth approximately $30,000. Canton Hathaway LLC bought a new stake in Moderna during the 1st quarter worth approximately $31,000. Archer Investment Corp acquired a new position in Moderna in the 2nd quarter valued at approximately $36,000. Finally, EverSource Wealth Advisors LLC increased its position in Moderna by 148.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock valued at $37,000 after acquiring an additional 801 shares during the period. 75.33% of the stock is currently owned by institutional investors.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions.

The company’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.